[go: up one dir, main page]

AR053575A1 - COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY - Google Patents

COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY

Info

Publication number
AR053575A1
AR053575A1 ARP060101410A ARP060101410A AR053575A1 AR 053575 A1 AR053575 A1 AR 053575A1 AR P060101410 A ARP060101410 A AR P060101410A AR P060101410 A ARP060101410 A AR P060101410A AR 053575 A1 AR053575 A1 AR 053575A1
Authority
AR
Argentina
Prior art keywords
controlled release
release formulation
combination
inhibitor
benign hyperplasia
Prior art date
Application number
ARP060101410A
Other languages
Spanish (es)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR053575A1 publication Critical patent/AR053575A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un procedimiento novedoso para el tratamiento de síntomas en hiperplasia benigna de prostata. A este respecto se usan de forma simultánea: (1) un antagonista del adrenoreceptor alfa-1 en formulacion de liberacion controlada o un inhibidor de 5-alfa- reductasa y (2) un inhibidor de PDE 5 de GMPc en formulacion de liberacion controlada o un inhibidor de PDE 5 de GMPc con mayor tiempo de semivida. Reivindicacion 2: Forma farmacéutica segun la reivindicacion 1, que contiene una formulacion de liberacion controlada de tamsulosina, alfuzosina, doxazosina o terazosina así como una formulacion de liberacion controlada de vardenafilo o sildenafilo. Reivindicacion 3: Forma farmacéutica segun la reivindicacion 1, que contiene una formulacion de liberacion controlada de tamsulosina, alfuzosina, doxazosina o terazosina así como tadalafilo.A novel procedure for the treatment of symptoms in benign prostatic hyperplasia. In this regard, the following are used simultaneously: (1) an alpha-1 adrenoceptor antagonist in a controlled release formulation or a 5-alpha reductase inhibitor and (2) a cGMP PDE 5 inhibitor in a controlled release formulation or a cGMP 5 PDE inhibitor with longer half-life. Claim 2: Pharmaceutical form according to claim 1, containing a controlled release formulation of tamsulosin, alfuzosin, doxazosin or terazosin as well as a controlled release formulation of vardenafil or sildenafil. Claim 3: Pharmaceutical form according to claim 1, containing a controlled release formulation of tamsulosin, alfuzosin, doxazosin or terazosin as well as tadalafil.

ARP060101410A 2005-04-13 2006-04-11 COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY AR053575A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (en) 2005-04-13 2005-04-13 Combination therapy for benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
AR053575A1 true AR053575A1 (en) 2007-05-09

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101410A AR053575A1 (en) 2005-04-13 2006-04-11 COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY

Country Status (22)

Country Link
EP (1) EP1888075A1 (en)
JP (1) JP2008535877A (en)
KR (1) KR20080007252A (en)
CN (1) CN101193638A (en)
AR (1) AR053575A1 (en)
AU (1) AU2006233567A1 (en)
BR (1) BRPI0610634A2 (en)
CA (1) CA2605224A1 (en)
CR (1) CR9427A (en)
DE (1) DE102005016981A1 (en)
DO (1) DOP2006000074A (en)
GT (1) GT200600145A (en)
IL (1) IL186604A0 (en)
MA (1) MA29683B1 (en)
MX (1) MX2007012567A (en)
PE (1) PE20061338A1 (en)
RU (1) RU2007141518A (en)
SV (1) SV2008002477A (en)
TN (1) TNSN07385A1 (en)
TW (1) TW200716122A (en)
UY (1) UY29473A1 (en)
WO (1) WO2006108519A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
JP2009520806A (en) * 2005-12-21 2009-05-28 ファイザー・プロダクツ・インク Pharmaceutical combination of PDE-5 inhibitor and 5-α reductase inhibitor
MX2008016569A (en) * 2006-07-07 2009-01-30 Teva Pharma Solid compositions comprising tadalafil and at least one carrier.
DE102007028869A1 (en) 2007-06-22 2008-12-24 Ratiopharm Gmbh A process for the preparation of a medicament containing tadalafil
AU2008334933B2 (en) 2007-12-13 2016-01-21 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
WO2009076663A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US8885621B2 (en) 2010-04-26 2014-11-11 Intel Corporation Method, apparatus and system for switching traffic streams among multiple bands
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (en) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 Drug port cavity disintegrating tablet and preparation method thereof
KR102246657B1 (en) * 2013-06-28 2021-04-30 한미약품 주식회사 Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
AU2014293141A1 (en) 2013-07-23 2016-02-18 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
KR20150056443A (en) * 2013-11-15 2015-05-26 한미약품 주식회사 Composite formulation comprising tadalafil and amlodipine
WO2016003180A1 (en) * 2014-06-30 2016-01-07 한미약품 주식회사 Composite preparation comprising 5-α-reductase inhibitor-containing film coating layer, and method for producing the composite preparation
BR112016030731A2 (en) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd COMPOSITE PREPARATION, AND, METHOD OF PREPARATION OF A COMPOSITE PREPARATION
CN106659690B (en) * 2014-06-30 2020-08-18 韩美药品株式会社 Co-formulations comprising a film-coating layer containing the active ingredient
CN106999538A (en) * 2014-11-20 2017-08-01 阿勒根公司 Method and composition comprising minirin Yu alpha-2 adrenoceptor antagonist-combination
EA201891891A1 (en) * 2016-03-31 2019-04-30 Ханми Фарм. Ко., Лтд. COMBINED PREPARATION IN THE FORM OF CAPSULE, CONTAINING TADALAFIL AND TAMSULASIN AND OWNING IMPROVED STABILITY AND DISSOLUTION RATE
KR101835506B1 (en) * 2016-10-25 2018-03-07 주식회사 에스텍파마 Rapid-acting mixture of tablet containing dutasteride and tadalafil
CN108066347B (en) * 2016-11-16 2021-02-02 深圳万和制药有限公司 Orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride
KR101879133B1 (en) * 2017-07-11 2018-07-17 (주)동구바이오제약 Agents for preventing or treating urinary disease and preparing the same
TR201715231A2 (en) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
EP1888075A1 (en) 2008-02-20
DE102005016981A1 (en) 2006-10-19
TNSN07385A1 (en) 2009-03-17
IL186604A0 (en) 2008-01-20
CA2605224A1 (en) 2006-10-19
TW200716122A (en) 2007-05-01
MX2007012567A (en) 2007-12-10
SV2008002477A (en) 2008-02-08
MA29683B1 (en) 2008-08-01
AU2006233567A1 (en) 2006-10-19
JP2008535877A (en) 2008-09-04
CR9427A (en) 2007-12-17
GT200600145A (en) 2007-04-10
DOP2006000074A (en) 2006-10-15
UY29473A1 (en) 2006-11-30
RU2007141518A (en) 2009-05-20
CN101193638A (en) 2008-06-04
PE20061338A1 (en) 2007-01-28
BRPI0610634A2 (en) 2010-07-13
KR20080007252A (en) 2008-01-17
WO2006108519A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
AR053575A1 (en) COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY
DOP2022000096A (en) CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
ECSP109934A (en) COMPOUND - 946
AR048819A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
AR045179A1 (en) USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND OF CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER
CO6612228A2 (en) Jak2 inhibitors and their use in the treatment of myeloproliferative diseases and cancer
WO2015193740A3 (en) Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
MX2020010412A (en) Inhibitors of bruton's tyrosine kinase.
CL2008001364A1 (en) Use of compounds derived from imidazol (1,2-b) pyridazine and pyrazolo (1,5-a) pyrimidine tyrosine kinase inhibitors pi-to treat benign or malignant tumor, among others; imidazole (1,2-b) pyridazine and pyrazolo (1,5-a) pyrimidine compounds; pharmaceutical compositions; and method of preparing compounds.
CR11100A (en) USE OF P13K-ALFA PYRIDOPIRIMIDINONE INHIBITORS IN CANCER TREATMENT
CR11499A (en) COMPOUNDS CONTAINING QUINOXALINE AS INHIBITORS OF THE HEPATITIS C VIRUS
PE20151070A1 (en) TYROSINE INHIBITORS - BRUTON KINASE
AR091876A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ECSP066990A (en) FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
CO2017004517A2 (en) Inhibitors of bruton tyrosine kinases derived from 2, 3, 4, 9-tetrahydro-ih-carbazole-8-carboxamide and 9h-carbazole-l-carboxamide, compositions comprising them and methods of preparation
CR20190517A (en) BENZOAZEPINE ANALOGUES AS INHIBITING AGENTS OF BRUTON TYROSINE KINASE
CR20130459A (en) DERIVATIVES OF PIRIDINIL- AND PIRAZINIL-METILOXI-ARIL USEFUL AS INHIBITORS OF TIROSINA CINASA DEL BAZO (Syk)
PE20141035A1 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER USING THE PI3KBETA INHIBITOR AND THE MAPK VIA INHIBITOR, INCLUDING MEK AND RAF INHIBITORS
CL2007001748A1 (en) Compound derived from 2-arylamino-4-aminopyrimidines, c-alpha protein kinase inhibitors; pharmaceutical compositions containing them; and its use to treat or prevent diabetes, cancer, cardiovascular diseases and others.
CL2007003251A1 (en) Compounds derived from substituted 1H-pyrazoles, inhibitors of kinase-catalyzed reactions; its preparation procedure; pharmaceutical composition; intermediate compounds; use of the main compounds, useful in the treatment of cancer.
UY33790A (en) COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND MEK INHIBITOR.
AR085399A1 (en) ANTITUMORAL COMBINATION INCLUDING CABAZITAXEL AND CISPLATINO
PE20220250A1 (en) USE OF DOCETAXEL IN THE TREATMENT OF CANCER THROUGH CONTROL OF MAXIMUM LEVELS IN PLASMA
CL2021001830A1 (en) lta4h inhibitors for the treatment of hidradenitis suppurativa
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
FB Suspension of granting procedure